# Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

> **NCT07689175** · PHASE2 · RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 60 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab (3 mg/kg)

## Key facts

- **NCT ID:** NCT07689175
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-21
- **Primary completion:** 2031-10-31
- **Final completion:** 2032-10-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07689175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07689175, "Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07689175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*